Low molecular weight heparin decreases pro-coagulant activity in clinical MSC products.
Schriner JB., Triolo F., Gill BS., Cardenas JC., Olson SD., Cox CS.
Laboratory Study on Face & Skin, published in Cytotherapy (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cytotherapy (2023)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 38127031
- DOI
- 10.1016/j.jcyt.2023.11.010
Abstract (original English)
Mesenchymal stromal cells (MSCs) are multipotent adult cells that can be isolated from tissues including bone marrow [MSC(BM)], adipose [MSC(AT)] and umbilical cord [MSC(CT)]. Previous studies have linked expression of tissue factor (TF) on MSC surfaces to a procoagulant effect. Venous thromboembolism (VTE), immediate blood-mediated inflammatory reaction (IBMIR) and microvascular thrombosis remain a risk with intravascular MSC therapy. We examined the effect of low molecular weight heparin (LMWH) on clinical-grade MSCs using calibrated automated thrombography (CAT). Clinical grade MSC(BM)s, MSC(AT)s and MSC(CT)s harvested at passage 4 were added to normal pooled plasma (NPP) to a final concentration of either 400 000 or 50 000 cells/mL. LMWH was added to plasma in increments of 0.1 U/mL. Thrombin generation (TG) was measured using CAT. Flow cytometry was conducted on the cells to measure MSC phenotype and TF load. Presence of MSCs decreased lag time and increased peak TG. All cell lines demonstrated a dose response to LMWH, with MSC(AT) demonstrating the least thrombogenicity and most sensitivity to LMWH. TG was significantly reduced in all cell lines at doses of 0.2 U/mL LMWH and higher. All MSC types and concentrations had a decrease in peak thrombin and TG with increasing amounts of LMWH. While this in vitro study cannot determine optimal dosing, it suggests that LMWH can be
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Oncologic safety of autologous fat grafting in head and neck cancer patients: A scoping review.
Systematic Review with a reported sample of 116 on Face & Skin, published in Med Oral Patol Oral Cir Bucal (2026) — summary generated from the PubMed abstract.
- 2026
- n = 116
Med Oral Patol Oral Cir Bucal - Level ASystematic ReviewEurope PMC
Stem cell-derived exosomes in tissue regeneration of oral and maxillofacial region: A systematic review
Systematic Review on Chronic Wound, published in Medicine (Baltimore) (2026) — summary generated from the PubMed abstract.
- 2026
Medicine (Baltimore) - Level AMeta-analysisPubMed
Stromal Vascular Fraction-Assisted Fat Grafting: A Systematic Review and Meta-analysis of Clinical Outcomes.
Meta-analysis on Face & Skin, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.
- 2026
Aesthetic Plast Surg - Level ASystematic ReviewEurope PMC
Applications of Exosomes in Female Medicine: A Systematic Review of Molecular Biology, Diagnostic and Therapeutic Perspectives
Systematic Review on Face & Skin, Systemic / IV, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci2 citations - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Osteogenic and Biocompatibility Potential of Polylactic Acid-Based Materials: A Systematic Review of Human Primary Cells Studies
Systematic Review on Face & Skin, published in J Funct Biomater (2026) — summary generated from the PubMed abstract.
- 2026
J Funct Biomater